Location History:
- Tempe, AZ (US) (2021 - 2024)
- Glendale, AZ (US) (2022 - 2024)
Company Filing History:
4 out of 1,736 
2 out of 3,539 
2 out of 2,347 
Years Active: 2021-2024
Title: Innovations and Contributions of Inventor Jie Wang
Introduction
Jie Wang is a prominent inventor based in Tempe, AZ, known for his significant contributions to the field of biomedical research. With a total of four patents to his name, Wang has focused on developing innovative solutions for early cancer detection and affinity reagent screening.
Latest Patents
One of Wang's latest patents is centered around plasma autoantibody biomarkers for basal-like breast cancer. This research highlights how cancer patients produce antibodies to tumor-derived proteins, which can serve as potential biomarkers for early detection. In this study, twenty-eight antigens have been identified as promising candidates for the early detection of basal-like breast cancer. Additionally, a 13-AAb classifier has been developed, which differentiates patients with basal-like breast cancer from healthy controls, achieving 33% sensitivity at 98% specificity. Another notable patent involves generating recombinant affinity reagents with arrayed targets. This method allows for the simultaneous screening of affinity reagents for multiple target proteins, utilizing arrayed targets such as peptides, proteins, RNA, and cells to enhance the throughput of discovering recombinant affinity reagents.
Career Highlights
Jie Wang has had a distinguished career, working with esteemed institutions such as Arizona State University and the National Institutes of Health, a component of the US Department of Health & Human Services. His work has significantly advanced the understanding of cancer biomarkers and affinity reagent technologies.
Collaborations
Wang has collaborated with notable colleagues, including Joshua LaBaer and Ji Qiu, contributing to various research projects that aim to improve cancer detection and treatment methodologies.
Conclusion
Jie Wang's innovative work in the field of biomedical research has led to significant advancements in cancer detection and affinity reagent technologies. His contributions continue to impact the scientific community and improve patient outcomes.